$4.61
0.00%
Nasdaq, Fri, Sep 25 2026.
ISIN
US8883143096
Symbol
TTNP

Titan Pharmaceuticals, Inc. Stock price

$4.61
+0.00 0.00% 1M
+0.00 0.00% 6M
+0.00 0.00% YTD
+0.58 14.39% 1Y
-4.68 50.38% 3Y
-34.59 88.24% 5Y
-21,379.39 99.98% 10Y
+2.42 110.50% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
+0.00 0.00%
ISIN
US8883143096
Symbol
TTNP
Industry

Is Titan Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$2.8m
Shares outstanding
1.3m
Valuation (TTM | estimate)
P/E
-
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
83.6%
Return on Equity
-192.9%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
$-2.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
59.3%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
$-2.1
Short interest
4.3%
Employees
4
Rev per Employee
$0.0

Titan Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Titan Pharmaceuticals, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Titan Pharmaceuticals, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Titan Pharmaceuticals, Inc.

Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.56 4.56
18% 18%
-
- Research and Development Expense - -
-
-
-4.55 -4.55
37% 37%
-
- Depreciation and Amortization 0.01 0.01
91% 91%
-
EBIT (Operating Income) EBIT -4.56 -4.56
37% 37%
-
Net Profit -4.71 -4.71
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Titan Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.

Head office United States
CEO Mr. Chay
Employees 4
Founded 1992
Website www.titanpharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today